Macrodantin (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive compounds that disrupt carbohydrate metabolism, impairing DNA, RNA and protein synthesis in the bacteria. This leads to bacterial cell death, particularly in the urinary tract where the drug concentrates.

The dosage of Macrodantin is determined by the prescribing clinician based on the infection severity, patient renal function and local guidelines. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Nitrofurantoin is classified as pregnancy category B, indicating no evidence of risk in animal studies but limited human data. It is generally avoided near term and during breastfeeding unless the benefits outweigh potential risks, as decided by a healthcare professional.

To order Macrodantin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other agents such as trimethoprim‑sulfamethoxazole, nitrofurantoin has a narrow spectrum focused on common urinary pathogens and achieves high urinary concentrations. It is often chosen when resistance to broader agents is a concern, though it may be contraindicated in renal impairment.

Macrodantin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Macrodantin is taken orally with a full glass of water, usually with food to reduce gastrointestinal upset. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare provider.

Serious risks include pulmonary toxicity (interstitial lung disease or fibrosis), hepatic injury, and hemolytic anemia, especially in patients with glucose‑6‑phosphate dehydrogenase deficiency. Prompt medical attention is required if symptoms such as persistent cough, jaundice or dark urine develop.

Macrodantin should be avoided in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to nitrofurantoin, G6PD deficiency, and in late pregnancy unless the prescriber determines the benefits outweigh the risks.